A scoping review on AI/ML-driven in-silico design of nanotechnology-based mRNA therapeutics: advances, challenges, and prospects
mRNA therapeutics are being formulated for cancer immunotherapy, cell therapy and gene therapy. Nevertheless, these therapeutics remain constrained due to manufacturing expenses, bioavailability and stability. Artificial intelligence (AI) and machine learning (ML) accelerate development through in silico validation and virtual screening. These allow formulation optimization, library screening, binding prediction, and rapid analysis; reducing time duration and labor. Yet, data heterogeneity across nanoparticle repositories and mRNA databases due to poor data standards, model inconsistency and literature gaps decreases the ease of clinical translation. Thus, generating standardized datasets connecting with LNP parameters with mRNA features, validating predictions throughout the therapeutic process and creating models linking molecular and systemic scales is essential, provided that the integration of nanomedicine, AI/ML and mRNA aids to formulate precise, personalized and economical therapeutics that are suitable for large scale implementation.
Authors
- Abhijit Vyas (ORCID: https://orcid.org/0000-0002-8264-9414)
- Varnitha Manikantan
- Tahsin Bennur (ORCID: https://orcid.org/0000-0002-9263-4064)
- Samruddhi Kaknale
- Jahnavi Jirage
Institutions
- Manipal Academy of Higher Education (IN)
- Symbiosis International University (IN)
- Bharati Vidyapeeth (Deemed to be University) (IN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s12967-026-09229-0
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00